JP2021514945A5 - - Google Patents
Info
- Publication number
- JP2021514945A5 JP2021514945A5 JP2020543140A JP2020543140A JP2021514945A5 JP 2021514945 A5 JP2021514945 A5 JP 2021514945A5 JP 2020543140 A JP2020543140 A JP 2020543140A JP 2020543140 A JP2020543140 A JP 2020543140A JP 2021514945 A5 JP2021514945 A5 JP 2021514945A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- pharmaceutical composition
- composition according
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023138517A JP2023159403A (ja) | 2018-02-26 | 2023-08-29 | がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635033P | 2018-02-26 | 2018-02-26 | |
| US62/635,033 | 2018-02-26 | ||
| US201862767900P | 2018-11-15 | 2018-11-15 | |
| US62/767,900 | 2018-11-15 | ||
| PCT/US2019/019340 WO2019165340A1 (en) | 2018-02-26 | 2019-02-25 | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023138517A Division JP2023159403A (ja) | 2018-02-26 | 2023-08-29 | がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514945A JP2021514945A (ja) | 2021-06-17 |
| JP2021514945A5 true JP2021514945A5 (enExample) | 2022-02-18 |
| JP7358365B2 JP7358365B2 (ja) | 2023-10-10 |
Family
ID=67688449
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543140A Active JP7358365B2 (ja) | 2018-02-26 | 2019-02-25 | がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 |
| JP2023138517A Pending JP2023159403A (ja) | 2018-02-26 | 2023-08-29 | がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023138517A Pending JP2023159403A (ja) | 2018-02-26 | 2023-08-29 | がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200392239A1 (enExample) |
| EP (1) | EP3759229A4 (enExample) |
| JP (2) | JP7358365B2 (enExample) |
| KR (1) | KR20200123782A (enExample) |
| CN (1) | CN111757941A (enExample) |
| AU (1) | AU2019224136A1 (enExample) |
| CA (1) | CA3091140A1 (enExample) |
| WO (1) | WO2019165340A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| EP4011910A1 (en) | 2014-04-03 | 2022-06-15 | IGM Biosciences, Inc. | Modified j-chain |
| PT3247728T (pt) | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| KR102357312B1 (ko) | 2015-03-04 | 2022-02-03 | 아이쥐엠 바이오사이언스 인코포레이티드 | Ｃｄ20 결합 분자 및 그의 용도 |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| AU2016249404B2 (en) | 2015-04-17 | 2021-01-21 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| PT3355913T (pt) | 2015-09-30 | 2024-12-18 | Igm Biosciences Inc | Moléculas de ligação com cadeia j modificada |
| ES2819870T3 (es) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
| WO2017196867A1 (en) | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| CA3055790A1 (en) | 2017-04-07 | 2018-10-11 | Igm Biosciences, Inc. | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| JP2022544405A (ja) | 2019-08-15 | 2022-10-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 免疫刺激性多量体型結合分子 |
| JP2023522962A (ja) | 2020-04-22 | 2023-06-01 | アイジーエム バイオサイエンシズ インコーポレイテッド | Ｐｄ－１アゴニスト多量体結合分子 |
| MX2022014259A (es) * | 2020-05-12 | 2022-12-07 | Igm Biosciences Inc | Uso de una molecula de union anti-dr5 multimerica en combinacion con una terapia contra el cancer para tratar el cancer. |
| WO2022154664A1 (en) * | 2021-01-15 | 2022-07-21 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer |
| US12600801B2 (en) | 2022-07-11 | 2026-04-14 | Fred Hutchinson Cancer Center | Single-domain antibodies that bind ROR1 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080248046A1 (en) * | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| CN100427505C (zh) * | 2004-08-19 | 2008-10-22 | 中国医学科学院基础医学研究所 | 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途 |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| WO2008066854A2 (en) * | 2006-11-28 | 2008-06-05 | Novartis Ag | Methods and compositions for inducing apoptosis in cancer cells |
| CN101820913A (zh) | 2007-08-09 | 2010-09-01 | 第一三共株式会社 | 在表达含死亡结构域的受体的细胞中诱导细胞凋亡的免疫脂质体 |
| BR112013010574A2 (pt) | 2010-10-29 | 2016-08-09 | Daiichi Sankyo Co Ltd | anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo |
| EP2760891B1 (en) | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
| EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| ES2812208T3 (es) * | 2013-03-14 | 2021-03-16 | Bristol Myers Squibb Co | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso |
| PT3247728T (pt) | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| ES2819870T3 (es) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
-
2019
- 2019-02-25 EP EP19757688.7A patent/EP3759229A4/en not_active Withdrawn
- 2019-02-25 WO PCT/US2019/019340 patent/WO2019165340A1/en not_active Ceased
- 2019-02-25 CA CA3091140A patent/CA3091140A1/en active Pending
- 2019-02-25 CN CN201980014868.8A patent/CN111757941A/zh active Pending
- 2019-02-25 AU AU2019224136A patent/AU2019224136A1/en not_active Abandoned
- 2019-02-25 KR KR1020207023440A patent/KR20200123782A/ko not_active Ceased
- 2019-02-25 JP JP2020543140A patent/JP7358365B2/ja active Active
- 2019-02-25 US US16/975,438 patent/US20200392239A1/en not_active Abandoned
-
2023
- 2023-08-29 JP JP2023138517A patent/JP2023159403A/ja active Pending